Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided EPS guidance of -0.330–0.280 for the period, compared to the consensus EPS estimate of -0.300. The company issued revenue guidance of $747.0 million-$753.0 million, compared to the consensus revenue estimate of $750.9 million. […]